Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-0.47% $36.26
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 5 971.66 mill |
EPS: | -3.86 |
P/E: | -9.39 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 164.69 mill |
Avg Daily Volume: | 1.456 mill |
RATING 2024-04-23 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | |||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -9.39 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.60x |
Company: PE -9.39 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$4.93 (-86.41%) $-31.33 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 34.93 - 37.59 ( +/- 3.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-10 | Goldsmith Mark A | Sell | 7 500 | Common Stock |
2024-04-10 | Goldsmith Mark A | Sell | 5 000 | Common Stock |
2024-04-10 | Goldsmith Mark A | Sell | 5 000 | Common Stock |
2024-04-10 | Patel Sushil | Sell | 2 155 | Stock Option (Right to Buy) |
2024-04-10 | Patel Sushil | Buy | 2 155 | Common Stock |
INSIDER POWER |
---|
73.04 |
Last 99 transactions |
Buy: 5 403 428 | Sell: 788 601 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $36.26 (-0.47% ) |
Volume | 1.341 mill |
Avg. Vol. | 1.456 mill |
% of Avg. Vol | 92.10 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $30.56 | N/A | Active |
---|
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.